AbbVie Files for Subcutaneous Induction of SKYRIZI in Crohn’s Disease

AbbVie has submitted a new application to the U.S. Food and Drug Administration seeking approval for a subcutaneous (SC) induction regimen of SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn’s disease.

If approved, this would expand dosing flexibility for patients, offering an alternative to the currently approved intravenous (IV) induction approach.

What’s Changing: From IV to Subcutaneous Induction

SKYRIZI is already approved for:

• IV induction
• SC maintenance dosing every eight weeks

The new application aims to add:

• Subcutaneous induction option

Why This Matters?

• Eliminates the need for infusion centers during induction
• Improves convenience and accessibility
• Aligns induction and maintenance into a fully SC-based regimen

This shift reflects a broader industry push toward patient-friendly, self-administered biologics.

Clinical Backing: Phase 3 AFFIRM Study

The submission is supported by data from the Phase 3 AFFIRM trial (NCT06063967).

Study Design

• Global, randomized, double-blind, placebo-controlled
• 289 patients with moderately to severely active Crohn’s disease
• 2:1 randomization (SKYRIZI SC vs placebo)

Patient Profile

• 65% had failed prior advanced therapies
• Balanced baseline characteristics across groups

Key Endpoints (Week 12)

• Clinical remission (CDAI <150)
• Endoscopic response

The study demonstrated positive efficacy and safety outcomes, supporting SC induction as a viable alternative to IV dosing.

About SKYRIZI: Targeting IL-23

SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively binds to the p19 subunit of the cytokine.

Mechanism of Action

• Blocks IL-23 signaling
• Reduces inflammatory pathways
• Helps control immune-mediated diseases

SKYRIZI was the first IL-23 specific inhibitor approved for Crohn’s disease in 2022.

Approved Indications Include

• Plaque psoriasis
• Psoriatic arthritis
• Crohn’s disease
• Ulcerative colitis

Disease Context: Crohn’s Disease

Crohn's disease is a progressive inflammatory condition affecting the gastrointestinal tract.

Common Symptoms

• Persistent diarrhea
• Abdominal pain
• Fatigue
• Weight loss

The disease is unpredictable and often extends beyond physical symptoms, impacting emotional health and daily functioning. In the United States alone, approximately 1 million people live with Crohn’s disease.

Safety Considerations

As with other immunomodulators, SKYRIZI carries important safety considerations.

Key Risks

• Serious allergic reactions
• Increased risk of infections
• Potential liver-related adverse events

Common Side Effects

• Upper respiratory infections
• Headache
• Joint pain
• Injection site reactions
• Abdominal pain

Patients are typically screened for infections, including tuberculosis, before initiating treatment.

Strategic Implications for AbbVie

This filing is less about a new drug—and more about lifecycle optimization.

Why It Matters?

• Expands dosing flexibility
• Improves patient adherence potential
• Strengthens competitive positioning in IBD

AbbVie is doubling down on immunology, where convenience and differentiation increasingly drive market share.

The Bigger Trend: Convenience as a Competitive Edge

Biologics are evolving beyond efficacy alone. The new battleground includes:

• Route of administration
• Treatment convenience
• Reduced healthcare system burden

A fully subcutaneous induction-to-maintenance pathway could:

• Reduce hospital visits
• Lower administration costs
• Improve patient experience

Final Takeaway

AbbVie’s FDA submission for subcutaneous induction of SKYRIZI signals a strategic push toward more flexible, patient-centric treatment models in Crohn’s disease.

If approved, it would:

• Provide an alternative to IV induction
• Simplify treatment pathways
• Reinforce SKYRIZI’s position in the IBD market

In a crowded immunology landscape, convenience is no longer optional—it is a differentiator.